VivoSeq
Other

Non-Squamous NSCLC

0

Pipeline Programs↗

13

Active Trials↗

8

Companies Involved↗

Non-squamous NSCLC is an early-stage landscape with 0 programs across 8 companies. The most active players are AstraZeneca, Pfizer, Veeda Oncology.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

53/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalV

Veeda Oncology

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalS

Sichuan Baili Pharmaceutical Co., Ltd.

0 programs

PreclinicalB

BeyondSpring Pharmaceuticals Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

40

clinical trials

Unknown status12 · 30%
Completed8 · 20%
Terminated6 · 15%
Active, not recruiting5 · 13%
Recruiting4 · 10%
Not yet recruiting4 · 10%
Other1 · 3%

Clinical Trials

Trial Activity

40 trials

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT04686305·244 enrolled
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Recruiting·FFudan University·Phase 2·NCT04136535·105 enrolled
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Recruiting·UUniversity Hospital Heidelberg·Phase 2·NCT04865250·20 enrolled
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT07264816·80 enrolled
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
Active, not recruiting·UUniversity of Utah·Phase 2·NCT04163432·43 enrolled
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
Active, not recruiting·SShanghai Chest Hospital·Phase 2·NCT05751187·54 enrolled
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Active, not recruiting·GGeorgetown University·Phase 2·NCT04958811·29 enrolled
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
Active, not recruiting·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 1/2·NCT05882734·61 enrolled
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03057106·301 enrolled
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
Not yet recruiting·GGuangdong Association of Clinical Trials·Phase 2·NCT07134413·77 enrolled
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT05962021·126 enrolled
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
Not yet recruiting·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT07361484·442 enrolled
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Not yet recruiting·GGuangdong Association of Clinical Trials·Phase 2·NCT07416058·61 enrolled
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04447118·151 enrolled
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Completed·CCanadian Cancer Trials Group·Phase 2·NCT02337530·62 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)